Initially developed for glycemic control in type 2 diabetes mellitus, GLP-1 RAs were first approved in the early 2000s, with agents like exenatide and liraglutide demonstrating robust glucose-lowering effects. The gene discussed is GLP1R; the disease is diabetes mellitus.